trending Market Intelligence /marketintelligence/en/news-insights/trending/yxe9otjmzjzddzlnroqymq2 content esgSubNav
In This List

Trillium Therapeutics appoints chief medical officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Trillium Therapeutics appoints chief medical officer

Trillium Therapeutics Inc. appointed Yaping Shou as chief medical officer.

Shou joins Trillium from Takeda Pharmaceutical Co. Ltd., where she most recently served as executive medical director.

Ontario-based Trillium Therapeutics is a clinical-stage immuno-oncology company developing therapies for the treatment of cancer.